Benjamin F. Edwards & Company’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Benjamin F. Edwards & Company’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$10K	Sell	426 -1,047	-71%	-$24.5K	﹤0.01%	1722
2024 Q1	$35K	Sell	1,473 -122	-8%	-$2.86K	﹤0.01%	1399
2023 Q4	$37K	Sell	1,595 -219	-12%	-$4.4K	﹤0.01%	1325
2023 Q3	$37K	Hold	1,814	–	–	﹤0.01%	1137
2023 Q2	$42K	Buy	1,814 +234	+15%	+$5.61K	﹤0.01%	1132
2023 Q1	$37K	Buy	+1,580	New	+$39.5K	﹤0.01%	1163

Other funds holding IDNA

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.36B AUM 18.79% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Benjamin F. Edwards & Company's IDNA Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 71% in Q2 2024, selling an estimated $24.5K and leaving 426 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1722.

Benjamin F. Edwards & Company first reported a position in IDNA in Q1 2023 and has held it in 6 quarters since. The position peaked at $42K in Q2 2023. 62 funds tracked by Wall St. Rank hold IDNA as of Q2 2024.

Benjamin F. Edwards & Company held 426 shares of iShares Genomics Immunology and Healthcare ETF worth $10K as of Q2 2024.
Benjamin F. Edwards & Company sold 1,047 iShares Genomics Immunology and Healthcare ETF shares in Q2 2024, an estimated $24.5K.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1722 holding.
Benjamin F. Edwards & Company first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2023 and has held it in 6 quarters since.
Benjamin F. Edwards & Company's iShares Genomics Immunology and Healthcare ETF position peaked at $42K in Q2 2023.
62 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.